Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406
- Citation:
- J Thorac Oncol vol 6 (suppl 2) abstr O39.01
- Meeting Instance:
- IASLC (WCLC) 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 712
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- P. A. Janne X. Wang M. A. Socinski J. Crawford L. Gu M. Capelletti M. J. Edelman M. A. Villalona-Calero R. A. Kratzke E. E. Vokes V. A. Miller
- Networks:
- Study
- CALGB-30406
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: